Detect STEMI and OMI
with Queen of Hearts™ AI ECG.

Queen of Hearts (QoH) is a clinically validated AI ECG model designed to accurately distinguish true STEMI (requiring emergent cathlab activation) from common mimics such as benign early repolarization (BER) and left ventricular hypertrophy (LVH). It was trained on a global dataset comprising millions of ECGs from chest pain patients, with robust outcome labels based on biomarker rule-out or angiographically confirmed STEMI, including STEMI-equivalent patterns indicative of Occlusion Myocardial Infarction (OMI).

The Queen of Hearts is a CE-marked medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. It has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA and is considered an investigational device in the US. Not for clinical use. Availability of features may vary by region.

Yes, the Queen of Hearts is built into the PMcardio platform, available for individuals or institutions. Download the PMcardio app and get the Queen of Hearts AI interpretation on any image of a 12-lead ECG within seconds.

The Queen of Hearts is a CE-marked medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. It has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA and is considered an investigational device in the US. Not for clinical use. Availability of features may vary by region.

Yes — in certain regions. Queen of Hearts is Class IIb medical device, CE-marked under the EU Medical Device Regulation (MDR) and approved for clinical use through the PMcardio platform.

In other regions, such as the United States, where it recently received FDA Breakthrough Device Designation it is currently available for research or investigational use pending FDA approval. Availability of features may vary by region.

For more information on regulatory status and compliance, please visit our Trust center.

Yes. The Queen of Hearts AI model is one of the most clinically validated cardiovascular AI tools to date, having undergone rigorous testing across diverse patient populations. It has been evaluated in thousands of real-world cases across North and South America, Europe, Asia, Australia, and Africa.

Key highlights from validation studies involving over 10,000 patients:

• 2× higher sensitivity than traditional criteria and standard-of-care interpretation
• 92% reduction in false-positive cath-lab activations due to common STEMI mimics (JACC: Cardiovascular Interventions, presented at TCT)
• 100% sensitivity for STEMIs that meet standard STEMI criteria
• Average of 48 minutes saved in door-to-balloon times following implementation

Beyond observational data: Queen of Hearts is currently the focus of multiple prospective clinical trials and randomized controlled studies (RCTs). These are being conducted across a range of clinical settings — including emergency departments, ambulance systems, and primary care — to further confirm its real-world impact, safety, and effectiveness.

Yes. Powered by the exclusive ECGxplain™ feature, Queen of Hearts offers built-in AI explainability (blue heat maps).

The model highlights specific ECG leads and segments that had the greatest diagnostic influence and provides a confidence score for each prediction. This helps you understand the reasoning behind the output, making it easier to interpret.

Learn more about AI explainability here.

Queen of Hearts is a clinical decision support tool, not a standalone diagnostic system. Just like a lab value, guideline recommendation, or scoring system, it provides clinicians with evidence-based insights to support, not replace, their medical judgment.

The responsibility for final clinical decisions remains with the healthcare provider. Physicians are expected to consider the AI output in the broader context of each patient's clinical presentation, history, and other diagnostics.

Re-running Queen of Hearts on serial ECGs helps detect evolving ischemia or dynamic changes. Currently, the AI model analyzes each ECG individually and does not yet compare serial ECGs over time.

However, in a recent study, Queen of Hearts identified 100% of STEMIs on the first ECG, compared to just 40% with traditional STEMI criteria — highlighting its ability to detect early signs of coronary occlusion even without serial input.

The Queen of Hearts is built to detect Occlusion MI (OMI) — acute coronary occlusion that often does not meet the classic STEMI ST-elevation threshold and is therefore missed by traditional criteria. By recognising these STEMI-equivalent patterns, QoH flags patients who need emergent cath-lab activation sooner. In one study it identified 100% of STEMIs on the first ECG versus 40% with traditional criteria.